0.9521
전일 마감가:
$1.00
열려 있는:
$0.96
하루 거래량:
124.06K
Relative Volume:
0.65
시가총액:
$40.54M
수익:
$135.87M
순이익/손실:
$72.20M
주가수익비율:
0.6705
EPS:
1.42
순현금흐름:
$45.09M
1주 성능:
-8.45%
1개월 성능:
-7.56%
6개월 성능:
-36.10%
1년 성능:
-35.23%
Scynexis Inc Stock (SCYX) Company Profile
명칭
Scynexis Inc
전화
201-884-5485
주소
1 EVERTRUST PLAZA, JERSEY CITY, NJ
SCYX을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
SCYX
Scynexis Inc
|
0.9521 | 40.54M | 135.87M | 72.20M | 45.09M | 1.42 |
![]()
ZTS
Zoetis Inc
|
164.65 | 73.07B | 9.26B | 2.49B | 2.30B | 5.47 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
14.87 | 47.43B | 30.25B | 1.37B | 5.08B | 0.4257 |
![]()
HLN
Haleon Plc Adr
|
10.29 | 45.72B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.37 | 17.71B | 16.54B | -1.64B | 749.00M | -1.45 |
![]()
UTHR
United Therapeutics Corp
|
308.27 | 14.37B | 2.76B | 1.11B | 898.10M | 22.77 |
Scynexis Inc Stock (SCYX) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2021-01-22 | 개시 | Guggenheim | Buy |
2021-01-06 | 개시 | Cantor Fitzgerald | Overweight |
2018-07-11 | 업그레이드 | Needham | Hold → Buy |
2018-06-27 | 개시 | Maxim Group | Buy |
2017-10-24 | 개시 | Guggenheim | Buy |
2017-07-10 | 개시 | ROTH Capital | Buy |
2017-05-09 | 다운그레이드 | Needham | Buy → Hold |
2017-03-03 | 재확인 | RBC Capital Mkts | Outperform |
2016-10-20 | 개시 | H.C. Wainwright | Buy |
2016-10-07 | 업그레이드 | WBB Securities | Buy → Strong Buy |
2016-10-03 | 재개 | Brean Capital | Buy |
2016-08-17 | 개시 | Guggenheim | Buy |
2016-08-09 | 재확인 | Needham | Buy |
2016-08-09 | 업그레이드 | WBB Securities | Speculative Buy → Buy |
2016-03-28 | 개시 | Brean Capital | Buy |
2015-12-29 | 개시 | WBB Securities | Speculative Buy |
2015-11-16 | 재확인 | RBC Capital Mkts | Outperform |
2015-06-10 | 개시 | Needham | Buy |
2014-05-29 | 개시 | Canaccord Genuity | Buy |
2014-05-29 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Scynexis Inc 주식(SCYX)의 최신 뉴스
SCYNEXIS (NASDAQ:SCYX) Lowered to Sell Rating by StockNews.com - Defense World
SCYNEXIS (SCYX) to Release Earnings on Thursday - Defense World
Research Analysts Issue Forecasts for SCYNEXIS FY2029 Earnings - Defense World
StockNews.com Downgrades SCYNEXIS (NASDAQ:SCYX) to Sell - Defense World
SCYNEXIS Full Year 2024 Earnings: Misses Expectations - Yahoo Finance
SCYNEXIS Reports 2024 Financial Results and Updates - TipRanks
Scynexis Inc earnings beat by $0.06, revenue fell short of estimates - Investing.com Australia
SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update - The Manila Times
SCYNEXIS, Inc. Advances Phase 1 Trial of SCY-247 Antifungal and Prepares for Phase 3 MARIO Study Restart - Nasdaq
SCYX stock touches 52-week low at $0.89 amid market challenges - Investing.com Australia
NanoNewron Appoints Industry Veteran Marco Taglietti, M.D., as Chief Executive Officer to Lead the Company and the Development of Their Promising Alzheimer’s Compound - Yahoo Finance
EQUITY ALERT: Levi & Korsinsky, LLP Notifies Shareholders of SCYNEXIS, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 8, 2017SCYX - ACCESS Newswire
SCYNEXIS (NASDAQ:SCYX) Stock Crosses Below 200-Day Moving Average – Time to Sell? - Defense World
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of SCYNEXIS, Inc. (SCYX) Investigation - ACCESS Newswire
SCYNEXIS (NASDAQ:SCYX) Share Price Passes Below 200-Day Moving Average – Should You Sell? - Defense World
Geode Capital Management LLC Acquires 36,405 Shares of SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World
FEDERATED HERMES, INC. Reduces Stake in SCYNEXIS Inc: A Detailed Analysis - GuruFocus.com
Aspergillosis Market Expected to rise, 2034 | Regeneron, Pulmocide, Astellas Pharma, Cipla, Pulmatrix, F2G, Cellix Bio, SCYNEXIS, TFF, Matinas BioPharma, Amplyx Pharmaceuticals, Cidara Therapeutics, I - The Globe and Mail
SCYNEXIS, Inc. (NASDAQ:SCYX) Short Interest Update - Defense World
Stay Ahead in Ophthalmology: Strategic Market Insights for Myopia Assessment & Forecasting | DelveInsight - GlobeNewswire Inc.
SCYX stock touches 52-week low at $0.97 amid market challenges - Investing.com
SCYNEXIS, Inc. Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections - Marketscreener.com
SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections - The Manila Times
SCYNEXIS Launches Pivotal Phase 1 Trial for Novel Antifungal Drug Against Deadly Infections - StockTitan
SCYX stock touches 52-week low at $1.15 amid market challenges - Investing.com Canada
Comparing Madrigal Pharmaceuticals (NASDAQ:MDGL) & SCYNEXIS (NASDAQ:SCYX) - Defense World
SCYNEXIS (NASDAQ:SCYX) adds US$6.5m to market cap in the past 7 days, though investors from five years ago are still down 86% - Simply Wall St
Avidity Partners Management LP's Strategic Acquisition in SCYNEX - GuruFocus.com
Federated Hermes, Inc. Increases Stake in SCYNEXIS Inc - GuruFocus.com
SCYX stock touches 52-week low at $1.25 amid market challenges By Investing.com - Investing.com South Africa
SCYX stock touches 52-week low at $1.25 amid market challenges - Investing.com
SCYNEXIS announces new $50 million equity sales agreement By Investing.com - Investing.com Australia
SCYNEXIS Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
Scynexis Inc earnings beat by $0.08, revenue fell short of estimates - Investing.com Canada
Scynexis: Q3 Earnings Snapshot - San Francisco Chronicle
SCYNEXIS announces new $50 million equity sales agreement - Investing.com India
SCYNEXIS Secures $10M GSK Milestone, Advances Antifungal Pipeline Despite Q3 Revenue Dip | SCYX Stock News - StockTitan
SCYNEXIS, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Scynexis Inc (SCYX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):